Last edition
News about "Phase 2 clinical study "
European Commission Approves Bavarian Nordic's MVA-BN Vaccine for Children Aged 2 and Older
Bavarian Nordic’s MVA-BN vaccine, Imvanex, is now authorised in the EU for children aged 2 years and older, expanding protection against mpox and smallpox among vulnerable populations.
Phase 2 Clinical Study | 10/08/2026 | By News Bureau
Mediar Therapeutics, Ono Pharma Enter Collaboration to Develop Novel Fibrosis Therapies
Mediar Therapeutics and Ono Pharmaceutical have entered a collaboration and option agreement to discover novel therapies targeting fibro-inflammatory diseases, while Mediar advances its pipeline of fibrosis-focused antibody programmes.
Phase 2 Clinical Study | 10/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy